Published in Hum Mol Genet on May 11, 2004
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Decoding the fine-scale structure of a breast cancer genome and transcriptome. Genome Res (2006) 2.09
Mapping DNA structural variation in dogs. Genome Res (2008) 1.64
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res (2009) 1.56
All y'all need to know 'bout retroelements in cancer. Semin Cancer Biol (2010) 1.52
Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet (2015) 1.47
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br J Cancer (2007) 1.26
Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer (2005) 1.18
A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics (2007) 1.17
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) (2012) 1.12
The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl (2013) 1.11
Rad9 has a functional role in human prostate carcinogenesis. Cancer Res (2008) 1.09
Identification of ovarian cancer metastatic miRNAs. PLoS One (2013) 1.09
High resolution oligonucleotide CGH using DNA from archived prostate tissue. Prostate (2007) 1.05
Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am (2010) 1.02
Prognostic factors in prostate cancer. Diagn Pathol (2006) 0.99
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer (2006) 0.97
Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis (2009) 0.97
Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia (2006) 0.97
Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci U S A (2006) 0.97
Calling amplified haplotypes in next generation tumor sequence data. Genome Res (2011) 0.95
Detection of recurrent rearrangement breakpoints from copy number data. BMC Bioinformatics (2011) 0.94
The progress on genetic analysis of nasopharyngeal carcinoma. Comp Funct Genomics (2007) 0.91
Power to detect selective allelic amplification in genome-wide scans of tumor data. Bioinformatics (2009) 0.91
A novel approach to identify driver genes involved in androgen-independent prostate cancer. Mol Cancer (2014) 0.89
The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol (2012) 0.89
Contributions of Rad9 to tumorigenesis. J Cell Biochem (2012) 0.88
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate (2010) 0.88
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer (2006) 0.88
Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int (2005) 0.87
Mutational Landscape of Aggressive Prostate Tumors in African American Men. Cancer Res (2016) 0.85
An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning. J Mol Histol (2007) 0.83
An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis (2008) 0.83
The role of mRNA splicing in prostate cancer. Asian J Androl (2014) 0.82
Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis. Am J Pathol (2014) 0.82
TAGCNA: a method to identify significant consensus events of copy number alterations in cancer. PLoS One (2012) 0.81
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl (2016) 0.81
A survey of analysis software for array-comparative genomic hybridisation studies to detect copy number variation. Hum Genomics (2010) 0.80
Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients. Cancer Epidemiol Biomarkers Prev (2014) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat (2011) 0.76
Loss of heterozygosity at D8S262: an early genetic event of hepatocarcinogenesis. Diagn Pathol (2015) 0.75
Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget (2016) 0.75
A systems biology approach to defining metastatic biomarkers and signaling pathways. Wiley Interdiscip Rev Syst Biol Med (2010) 0.75
Decoding human liver cancer signatures. Gastrointest Cancer Res (2008) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Fine-scale structural variation of the human genome. Nat Genet (2005) 24.31
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet (2006) 7.70
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet (2004) 7.68
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45